The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicinVincenzo Quagliariello, Nicola Maurea, Michelino De Laurentiis et al.|Cardiovascular Diabetology|2021Cited by 368
Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathwaysVincenzo Quagliariello, Nicola Maurea, Margherita Passariello et al.|Frontiers in Cardiovascular Medicine|2022Cited by 48
Polydatin Reduces Cardiotoxicity and Enhances the Anticancer Effects of Sunitinib by Decreasing Pro-Oxidative Stress, Pro-Inflammatory Cytokines, and NLRP3 Inflammasome ExpressionVincenzo Quagliariello, Nicola Maurea, Massimiliano Berretta et al.|Frontiers in Oncology|2021Cited by 45
PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in CardioncologyVincenzo Quagliariello, Nicola Maurea, Irma Bisceglia et al.|Cancers|2023Cited by 42
Interleukin-1 blocking agents as promising strategy for prevention of anticancer drug-induced cardiotoxicities: possible implications in cancer patients with COVID-19.Vincenzo Quagliariello, Nicola Maurea, Andrea Paccone et al.|PubMed|2021Cited by 30